inequity in affected populations. In our studies, the youngest participant we have diagnosed 13 positive for schistosome infection was 6 months old, which is not unusual in high 14 schistosome transmission areas as has been reported in Nigeria [2] . Such observations re-15 affirm the need for interventions targeting pre-school children who continue to be excluded 16 from current national control programmes. Exclusion of these children from Mass Drug 17 Administration (MDA) programmes is similar to what was the situation for soil transmitted 18 helminths (STH) two decades ago [3] . In the case of STH, following concerted efforts laying 19 the evidence base for the inclusion of pre-school children in MDA programmes using the 20 antihelminthics albendazole (ALB) and mebendazole (MEB) and advocacy (see [3] ), pre-21 school children are now included in STH control programmes [4] . Primary school children in 22 some helminth endemic areas are benefiting from mass drug co-administration of PZQ and 23 ALB or MEB as is happening in Zimbabwe. Inclusion of the pre-school children in these programmes will be a significant step in improving child health and development in affected 1 areas.
2 3 Schistosome control programmes 4 Over the past decade, there has been a concerted global effort to control schistosomiasis in 5 Africa, galvanised initially by the Millennium Development Goal (MDG) 6 to combat 6 HIV/AIDS, malaria and other diseases by 2015 and the World Health Assembly resolution 7 54.19 to treat at least 75% of all school-age children at risk of schistosome morbidity by 8 2010. We conducted a review of publications quantifying the levels of Schistosoma 9 haematobium and S. mansoni the most prevalent human schistosome species occurring in 10 African children aged 5 years and below. Using this information we generated the first S. 11 haematobium and S. mansoni maps of paediatric schistosomiasis in Africa for the period 12 (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) shown in Figure 1 . The map represents all the information currently published 13 on the prevalence of paediatric schistosomiasis and highlights the paucity of data available in 14 this age group. Nevertheless, schistosome prevalences among preschool children are closely 15 related to those of the older children/adults in the same countries and this map is consistent 16 with those published for the older population [5] . Of the African countries where 17 schistosomiasis is endemic, 28 countries have or are currently implementing a 18 schistosomiasis control programme in the period 1995 -2013 as listed in the WHO database 19 on PC of neglected tropical diseases 20 (http://www.who.int/neglected_diseases/preventive_chemotherapy/en/). However, none of 21 them have included children aged 5 years and under, despite more that 60% of them reporting 22 significant schistosome infection levels in this age group (Figure 1 ). For control programmes 23 commenced before 2011 there are several reasons which were given for not treating children 24 aged 5 years and under, the main ones being 1) uncertainties in levels of exposure of this age group to infective water sources [6] , 2) uncertainties in the levels of infection and morbidity 1 in this age group [7] , 3) unknown safety and efficacy of PZQ, and 4) the involvement of the 2 host immune system acting in synergy with PZQ to clear schistosome worms [8] was 3 interpreted to suggest that the immune system of pre-school children would to be 4 immature/un-primed to act synergistically with PZQ [9, 10] . This review discusses in part, 5 the scientific research conducted by my group and those of others that challenged these 6 misconceptions and barriers to schistosome treatment of pre-school children culminating in 7 the revised recommendations from the WHO in 2010. Praziquantel was the first antihelminthic drug to fulfil the WHO's requirements for 11 population-based chemotherapy of a broad range of parasitic infections 12 (http://apps.who.int/medicinedocs/en/d/Jwhozip48e/6.html) and is on the WHO List of 13 Essential Medicines, a list of the most important medications needed in a basic health system. Structurally, PZQ is a racemic mixture of the dextro (right) and laevo (left) isomers of 2-24 (Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one, of which only the laevo isomer is active against schistosomes [13] . The pharmacokinetics have 1 not been studied in children aged 4 years and below, but studies in adults show that PZQ is 2 rapidly absorbed from the gastrointestinal tract so that maximal levels in human plasma occur 3 within 1to 2 hours of administration and the drug has a half-life of ~ 0.8 to 1.5 hours in adults 4 with normal renal and liver function [14] . It is taken as a single dose of 40 or 60mg/kg body 5 weight. The mode of action of PZQ is still to be fully described; however, the drug is thought with the host immune system [9] . The drug is not effective against immature worms [14] .
10
PZQ is efficacious with schistosome cure rates and egg reduction rates typically above 75% for several years (see review [28] ). Furthermore, the limited investigations describing and 23 quantifying morbidity in this age group have shown that the infections in the young children 24 are of clinical significance [34, 35] . Apart from the immediate effects of infection and disease 25 in the young children, childhood infections have long-term effects on host health as untreated 1 schistosome infections are chronic and disease is progressive, meaning that delayed treatment 2 (termed the PZQ gap[10]) can result in more severe forms of disease including bladder 3 cancer, liver damage[26], poor reproductive health and increased susceptibility to HIV 4 infection in adulthood [36] . Taken together, these studies corrected the misconceptions that 5 young children were not sufficiently exposed to be infected and that even if infected their 6 parasite burdens were too low to be of clinical significance [10] . This was the first and 7 considerable step towards highlighting the need for intervention in this age group. antibodies [8, 9, 37] . These observations gave rise to a belief that the childhood immune 13 system may be too immature or not sufficiently primed to synergise effectively with PZQ to 14 kill the parasites. Our earlier studies had shown this not to be the case; we demonstrated that 15 children as young as 4 months mounted schistosome-specific antibody responses [29, 38] . 16 Furthermore, work in Kenya showed that PZQ was as efficacious in schistosome infected 17 immunocompromised HIV patients as in non HIV+ volunteers [39] . These studies showed 18 that children aged 5 years were already immunologically primed to kill parasites damaged by 19 PZQ and that immunocompromisation did not affect PZQ efficacy.
21
Having established that there was no immunological reason to hinder with the action of PZQ 22 in young children, there still remained the lack of evidence on the safety and efficacy of PZQ 23 in this age group. Although PZQ could be prescribed on a case-by-case basis in young children, there had not been studies on the safety of PZQ treatment of schistosomiasis 1 infection in children under 5 years of age with a view to include them in MDA programmes.
2
In 2008 the World Health Organisation funded 3 groups, including our own, to formally 3 conduct studies determining the safety, efficacy and acceptability of PZQ for the treatment of 4 S. haematobium and S. mansoni in pre-school children in Africa [40] . All studies tested the 5 tablet PZQ formulation and one study tested both the tablet and paediatric liquid formulation. 6 These studies concluded that PZQ treatment of children aged 6 months -5 years was safe and 7 efficacious [40] . Our own study showed that the pre-school children reported significantly 8 fewer side effects than in the primary school children [16, 17] . The fewer side effects were 9 unsurprising as these are related to the intensity of infection [41] [42] [43] and infection intensities 10 are lower in this age group than in primary school aged children. We reported cure rates and 11 egg reduction rates above 90% in pre-school children [17] .These results and those from the 12 other groups were reviewed at a WHO working group meeting which made the 13 recommendations detailed below. Furthermore, our results informed the formulation of Operational aspects of Praziquantel administration to pre-school children 25 At the practical level, a challenge to treating pre-school children was how to determine the 1 dosage in the field. Our own experiences in the field with digital weighing scales 2 demonstrated their limited use as within a week of purchase, they were no longer functioning. Changing policy and practise 19 In response to concerted efforts by several scientists and health workers to highlight the 20 significant health inequity that was being perpetuated by exclusion of pre-school children Additionally, the working group called on the WHO to formally advocate the treatment of 19 this age group in areas where schistosomiasis is endemic, and for the WHO to call for 20 additional research to develop child friendly formulations of PZQ. Finally, the working group 21 made recommendations on operational issues. First, the PZQ dose pole for working out the 22 drug dosage used in the field would be a useful operational tool if it could be extended to 23 below 94 cm of height to incorporate the pre-school children. However, the pole had not been 24 evaluated for use in this age group. As detailed above a subsequent investigation lead by Stothard showed that the PZQ pole could be extended to be applicable in the pre-school aged 1 children [45] . Second, the size of the PZQ tablet and the need to break it into smaller units for 2 the young children made it cumbersome for use in the field. Therefore, there was need for the Thus, significant progress has been made at the policy level in addressing the health inequity 7 created by delayed treatment of childhood schistosomiasis. Optimal treatment regimen 24 There is still a need for information on the number, frequency and optimal timing of 1 treatment to control morbidity. Quantitative studies investigating the effects of frequency of 2 treatments on morbidity in primary school children indicated that early, and repeated 3 treatment is required to make a significant impact on stunting and malnutrition [54] . There 4 have been no such studies for the additional long-term schistosome -related morbidity such 5 as liver and bladder associated pathology, nor have there been any such studies in pre-school 6 children. In our recent studies funded by the Thrasher Research Fund, we have demonstrated 7 that infected pre-school children already suffer morbidity attributable to schistosome 8 infection (submitted), thus, it is important that current understanding of the progression of 9 schistosome morbidity is recalibrated to reflect the previously unacknowledged earlier onset 10 of morbidity in pre-school children [54] .
12
Control/intervention methods 13 To meet the vision of schistosome elimination, it is clear that it will be necessary to make 
23
The demonstration that S. haematobium, the most prevalent human schistosome species in 1 Africa can hybridise with cattle schistosomes S. bovis and S. currasoni [59, 60] , introduces a 2 zoonotic feature to the transmission dynamics, and presents the potential for schistosome 
